instruction:
Given a question and a context passage, generate the answer having the word or phrase from the context passage. Here, the answer should be a shortest continous span from the passage.
question:
Context: Coming off their Sunday night road win over the Packers, the Cowboys went home for a Week 4 NFC East showdown with the Washington Redskins. In the first quarter, the 'Boys shot first as QB Tony Romo completed a 21-yard TD pass to TE Jason Witten. In the second quarter, the Redskins took the lead as QB Jason Campbell completed a 3-yard TD pass to WR James Thrash and a 2-yard TD pass to WR Antwaan Randle El, along with kicker Shaun Suisham getting a 20-yard field goal. Dallas closed out the half with kicker Nick Folk getting a 36-yard field goal. In the third quarter, the Cowboys tied the game with Romo completing a 10-yard TD pass to WR Terrell Owens. Washington would respond with Suisham kicking a 33-yard field goal. In the fourth quarter, the Redskins increased their lead with Suisham nailing a 33-yard and a 29-yard field goal. The 'Boys tried to rally as Romo completed an 11-yard TD pass to WR Miles Austin. However, Dallas' onside kick attempt failed, preserving the Redskins' win. 
 Question: Which player scored the last field goal of the game?
answer:
shaun suisham


question:
Context: Marek was a farmer who lived in a village far away. One day he became very ill, and everyone thought he would die. They sent for a doctor, who arrived two days later and examined the sick man. The doctor asked for a pen and some paper to write down the name of the medicine. But there was no pen or paper in the village, because no one could read or write. The doctor picked up a piece of burnt wood from the fire. Using the wood, he wrote the name of the medicine on the door of the house. "Get this medicine for him," he said,"and he will soon get better." Marek's family and friends did not know what to do. They could not read the strange writing. Then the village baker had an idea. He took off the door of the house, put it on his cart and drove to the nearest town. He bought the medicine, and Marek was soon well again. He would not let anyone wash the magic words away from the door. 
 Question: On what did the doctor write the name of the medicine?
answer:
the door of the house.


question:
Context: The ubiquitin-proteasome pathway regulates many basic cellular processes and has been proven to be a promising target for cancer therapy. Bortezomib is the first U.S. Food and Drug Administration (FDA) approved proteasome inhibitor used in the treatment of newly diagnosed multiple myeloma, relapsed/refractory multiple myeloma, and mantle cell lymphoma. The anti-cancer mechanisms of bortezomib elucidated by preclinical studies include: upregulation of proapoptotic proteins (e.g., Noxa, IB), inhibition of NFB and its anti-apoptotic target genes, suppression of several anti-apoptotic proteins (e.g., Bcl-XL, Bcl-2, and STAT-3), down-regulation of expression of several proteins involved in DNA repair pathways, and induction of endoplasmic reticulum (ER) stress and pro-apoptotic Unfolded Protein Response (UPR). Bortezomib has potent chemo-/radio-sensitizing effects and can overcome traditional drug resistance in tumors when used in combination with potential chemotherapies. Although bortezomib has been successful in improving clinical outcomes when used in hematological malignancies, relapse may occur in those patients who responded initially. Furthermore, some cytotoxicities (such as peripheral neuropathy) were found to be associated with bortezomib treatment. These observations have encouraged researchers to search for the next generation proteasome inhibitors (including carfilzomib and marizomib) that could overcome bortezomib resistance and have improved properties, reduced toxicities, and broader anticancer activities, based on the lessons learned from the mechanisms and use of bortezomib. This review summarizes the current status of bortezomib as well as several other proteasome inhibitors that are currently under clinical and preclinical investigation. 
 Question: Which is the target of bortezomib used in cancer therapy?
answer:

the ubiquitin/proteasome pathway